Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?
- 20 April 2012
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 27 (2) , 119-122
Abstract
Stratified medicine is a new term that figures highly in current MRC and NHS strategy. It has developed from the earlier terms individualised or personalised medicine and refers to the use of genetic and/or endophenotypic measures to allow better targeting of treatments. The best exemplar is HER2 positivity in breast cancer to determine the efficacy of Herceptin. Clinical trials of this anti-cancer drug were initially unpromising, but once the HER2 positive subgroup was identified it was found, in this subgroup only, to be highly effective. It is presumed that similar subgroups will be found for many common disorders not just cancers, and that these will lead to much better targeted treatments. Such an advance may be necessary to develop new treatments in certain fields where the development of broad-spectrum/blockbuster treatments appears to have reached the end of the road; a particular example of this is in psychiatry. In this paper we discuss this issue in relation to psychiatry using a new and interesting example of how genotyping might help rescue an apparently failed novel treatment in anxiety disorders.Keywords
This publication has 22 references indexed in Scilit:
- An 18-kDa Translocator Protein (TSPO) Polymorphism Explains Differences in Binding Affinity of the PET Radioligand PBR28Journal of Cerebral Blood Flow & Metabolism, 2011
- Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein LigandsJournal of Nuclear Medicine, 2010
- Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brainSynapse, 2010
- Two Binding Sites for [3H]PBR28 in Human Brain: Implications for TSPO PET Imaging of NeuroinflammationJournal of Cerebral Blood Flow & Metabolism, 2010
- Comparison of [11C]-(R)-PK 11195 and [11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarkerNeuroImage, 2010
- Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side EffectsScience, 2009
- Cholesterol transport in steroid biosynthesis: Role of protein–protein interactions and implications in disease statesBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2009
- The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: From pathology to imagingProgress in Neurobiology, 2006
- The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brainPharmacology Biochemistry and Behavior, 2005
- Generalized anxiety disorder: comorbidity, comparative biology and treatmentInternational Journal of Neuropsychopharmacology, 2002